119 related articles for article (PubMed ID: 38153233)
21. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
23. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
[TBL] [Abstract][Full Text] [Related]
26. Lymph Node Positivity in One-Step Nucleic Acid Amplification is a Prognostic Factor for Postoperative Cancer Recurrence in Patients with Stage II Colorectal Cancer: A Prospective, Multicenter Study.
Itabashi M; Yamamoto H; Tomita N; Inomata M; Murata K; Hayashi S; Miyake Y; Igarashi S; Kato T; Noura S; Furuhata T; Ozawa H; Takemasa I; Yasui M; Takeyama H; Okamura S; Ohno Y; Matsuura N
Ann Surg Oncol; 2020 Apr; 27(4):1077-1083. PubMed ID: 31722072
[TBL] [Abstract][Full Text] [Related]
27. Identification of Prognostic Gene Signatures by Developing a scRNA-Seq-Based Integration Approach to Predict Recurrence and Chemotherapy Benefit in Stage II-III Colorectal Cancer.
Wang Z; Xing K; Zhang B; Zhang Y; Chai T; Geng J; Qin X; Zhang X; Xu C
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293319
[TBL] [Abstract][Full Text] [Related]
28. Elevated serum carcinoembryonic antigen level after curative surgery is a prognostic biomarker of stage II-III colorectal cancer.
Sonoda H; Yamada T; Matsuda A; Ohta R; Shinji S; Yokoyama Y; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Miyasaka T; Yoshida H
Eur J Surg Oncol; 2021 Nov; 47(11):2880-2887. PubMed ID: 34103245
[TBL] [Abstract][Full Text] [Related]
29. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.
Perez-Carbonell L; Balaguer F; Toiyama Y; Egoavil C; Rojas E; Guarinos C; Andreu M; Llor X; Castells A; Jover R; Boland CR; Goel A
PLoS One; 2014; 9(8):e104285. PubMed ID: 25127039
[TBL] [Abstract][Full Text] [Related]
30. MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.
Lenos K; Goos JA; Vuist IM; den Uil SH; Delis-van Diemen PM; Belt EJ; Stockmann HB; Bril H; de Wit M; Carvalho B; Giblett S; Pritchard CA; Meijer GA; van Kooyk Y; Fijneman RJ; van Vliet SJ
Oncotarget; 2015 Sep; 6(28):26278-90. PubMed ID: 26172302
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of perineural invasion in stages II and III colorectal cancer.
Zhou Y; Wang H; Gong H; Cao M; Zhang G; Wang Y
Pathol Res Pract; 2015 Nov; 211(11):839-44. PubMed ID: 26429129
[TBL] [Abstract][Full Text] [Related]
32. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
Lee JL; Roh SA; Kim CW; Kwon YH; Ha YJ; Kim SK; Kim SY; Cho DH; Kim YS; Kim JC
World J Gastroenterol; 2019 Mar; 25(11):1341-1354. PubMed ID: 30918427
[TBL] [Abstract][Full Text] [Related]
33. CXCL10 expression and prognostic significance in stage II and III colorectal cancer.
Jiang Z; Xu Y; Cai S
Mol Biol Rep; 2010 Jul; 37(6):3029-36. PubMed ID: 19821051
[TBL] [Abstract][Full Text] [Related]
34. A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer.
Li X; Jonnagaddala J; Yang S; Zhang H; Xu XS
J Cancer Res Clin Oncol; 2022 Aug; 148(8):1955-1963. PubMed ID: 35332389
[TBL] [Abstract][Full Text] [Related]
35. A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer.
Sho S; Court CM; Winograd P; Russell MM; Tomlinson JS
J Surg Oncol; 2017 Dec; 116(8):996-1004. PubMed ID: 28767131
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of prognostic nomograms based on De Ritis ratio and clinicopathological features for patients with stage II/III colorectal cancer.
Fu J; Du F; Tian T; Huang H; Zhang L; Li D; Liu Y; Zhang D; Gao L; Zheng T; Liu Y; Zhao Y
BMC Cancer; 2023 Jul; 23(1):620. PubMed ID: 37400788
[TBL] [Abstract][Full Text] [Related]
37. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
[TBL] [Abstract][Full Text] [Related]
38. Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.
Semaan A; Uhl B; Branchi V; Lingohr P; Bootz F; Kristiansen G; Kalff JC; Matthaei H; Pantelis D; Dietrich D
Clin Colorectal Cancer; 2018 Jun; 17(2):e385-e393. PubMed ID: 29580650
[TBL] [Abstract][Full Text] [Related]
39. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
40. Identification and characterization of ANO9 in stage II and III colorectal carcinoma.
Li C; Cai S; Wang X; Jiang Z
Oncotarget; 2015 Oct; 6(30):29324-34. PubMed ID: 26317553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
